论文部分内容阅读
为探讨癌基因 c-erBb-2和抑癌基因 nm-23的编码蛋白与鼻咽癌的关系,用免疫组化法对51例鼻咽癌组织中的两种蛋白产物进行检测,随访4年,对复发(死亡)组与未复发(存活)组间蛋白阳性率的差别进行比较。结果显示,未分化癌组 c-erBb-2和 nm-23蛋白阳性率为81.8%、27.3%,分别显著高于或低于高分化癌组的58.3%和50%(P<0.05);复发和死亡组 c-erBb-2(77.8%、79.2%)和 nm-23(33.3%、25%),分别高于或低于未复发组(58.3%、59.3%)及存活组(54.2%、51.9%),P<0.05。c-erBb-2蛋白阳性或 nm-23蛋白阴性组,复发死亡的发生概率较大。结论:癌基因 c-erBb-2和抑癌基因 nm-23的表达蛋白是了解病情、评估预后及复发死亡的临床检测指标之一。
To investigate the relationship between the expression of oncogene c-erBb-2 and tumor suppressor gene nm-23 and nasopharyngeal carcinoma, two protein products from 51 cases of nasopharyngeal carcinoma were detected by immunohistochemistry and followed up for 4 years , The difference between the positive rate of protein in the recurrence (death) group and the non-recurrence (survival) group was compared. The positive rates of c-erBb-2 and nm-23 in undifferentiated carcinoma were 81.8% and 27.3%, respectively, which were significantly higher or lower than those in well-differentiated carcinoma 58.3% and 50% (P <0.05) (33.3%, 25%) were higher or lower than those in the non-recurrence group (58.3%, 59.3%) and the survival group (54.2%, respectively) 51.9%), P <0.05. c-erBb-2 protein positive or nm-23 protein negative group, the probability of recurrence of death is greater. Conclusion: The expression of oncogene c-erBb-2 and tumor suppressor gene nm-23 is one of the clinical indicators for assessing the prognosis and prognosis.